NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free FOLD Stock Alerts $11.58 +0.10 (+0.87%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$11.38▼$11.8450-Day Range$11.48▼$14.0052-Week Range$9.70▼$14.57Volume2.33 million shsAverage Volume3.24 million shsMarket Capitalization$3.42 billionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amicus Therapeutics alerts: Email Address Amicus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.7% Upside$20.00 Price TargetShort InterestBearish10.46% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.80Based on 9 Articles This WeekInsider TradingSelling Shares$3.69 M Sold Last QuarterProj. Earnings Growth1,100.00%From $0.03 to $0.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector185th out of 947 stocksPharmaceutical Preparations Industry81st out of 435 stocks 3.5 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Amicus Therapeutics has a forecasted upside of 72.7% from its current price of $11.58.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.46% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 15.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 2.7 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Amicus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 15 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,693,174.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amicus Therapeutics is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow by 1,100.00% in the coming year, from $0.03 to $0.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -22.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -22.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 21.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Amicus Therapeutics Stock (NASDAQ:FOLD)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late-onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More FOLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesMarch 16, 2024 | insidertrades.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Director Sells $100,500.00 in StockMarch 16, 2024 | ca.finance.yahoo.comFOLD Jul 2024 12.000 callMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 7, 2024 | finance.yahoo.comFOLD Oct 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Jan 2025 12.000 putMarch 7, 2024 | finance.yahoo.comFOLD Jul 2024 9.000 putMarch 7, 2024 | finance.yahoo.comDirector Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)March 6, 2024 | finance.yahoo.comAmicus Therapeutics Stock Sees RS Rating Improve To 74March 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 2, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 1, 2024 | seekingalpha.comAmicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Amicus (FOLD), Xenon (XENE) and Veeva Systems (VEEV)March 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Amicus’s Strong Product Launch and Growth TrajectoryMarch 1, 2024 | finance.yahoo.comAmicus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 1, 2024 | globenewswire.comAmicus Therapeutics to Present at Upcoming Investor Conferences in March 2024February 29, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | seekingalpha.comAmicus Therapeutics: Expect Improved Commercial Momentum In 2024February 29, 2024 | finance.yahoo.comQ4 2023 Amicus Therapeutics Inc Earnings CallFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amicus with Strong Growth and Promising OutlookFebruary 28, 2024 | finanznachrichten.deAmicus Therapeutics, Inc.: Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate UpdatesFebruary 28, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Reports 21% Revenue Growth in 2023, Eyes Non-GAAP Profitability ...February 28, 2024 | msn.comAmicus Therapeutics Non-GAAP EPS of $0.01 beats by $0.05, revenue of $115.08M in-lineFebruary 28, 2024 | seekingalpha.comAmicus Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 28, 2024 | globenewswire.comAmicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate UpdatesFebruary 27, 2024 | msn.comAmicus Therapeutics Q4 2023 Earnings PreviewFebruary 15, 2024 | finance.yahoo.comAmicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024February 15, 2024 | globenewswire.comAmicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024See More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today3/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees517Year Founded2002Price Target and Rating Average Stock Price Target$20.00 High Stock Price Target$22.00 Low Stock Price Target$19.00 Potential Upside/Downside+72.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E Ratio386.00 P/E GrowthN/ANet Income$-151,580,000.00 Net Margins-37.96% Pretax Margin-37.59% Return on Equity-119.46% Return on Assets-20.40% Debt Debt-to-Equity Ratio2.42 Current Ratio2.88 Quick Ratio2.52 Sales & Book Value Annual Sales$399.36 million Price / Sales8.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book21.05Miscellaneous Outstanding Shares295,380,000Free Float289,180,000Market Cap$3.42 billion OptionableOptionable Beta0.77 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. John F. Crowley (Age 57)Executive Chairman Comp: $1.88MMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Comp: $733.94kMr. David M. Clark (Age 49)Chief People Officer Comp: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMore ExecutivesKey CompetitorsTurning Point TherapeuticsNASDAQ:TPTXAlkermesNASDAQ:ALKSBridgeBio PharmaNASDAQ:BBIOMadrigal PharmaceuticalsNASDAQ:MDGLDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,360,613 shares on 3/11/2024Ownership: 9.646%Wellington Management Group LLPBought 7,666,335 shares on 3/5/2024Ownership: 5.143%Margaret G McglynnSold 7,500 sharesTotal: $100,500.00 ($13.40/share)Goldman Sachs Group Inc.Sold 395,339 shares on 3/1/2024Ownership: 0.724%American International Group Inc.Bought 1,298 shares on 2/28/2024Ownership: 0.048%View All Insider TransactionsView All Institutional Transactions FOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price target for 2024? 4 brokers have issued twelve-month price targets for Amicus Therapeutics' shares. Their FOLD share price targets range from $19.00 to $22.00. On average, they anticipate the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2024? Amicus Therapeutics' stock was trading at $14.19 at the beginning of the year. Since then, FOLD stock has decreased by 18.4% and is now trading at $11.58. View the best growth stocks for 2024 here. Are investors shorting Amicus Therapeutics? Amicus Therapeutics saw a increase in short interest in February. As of February 29th, there was short interest totaling 30,910,000 shares, an increase of 15.4% from the February 14th total of 26,780,000 shares. Based on an average daily trading volume, of 3,280,000 shares, the days-to-cover ratio is presently 9.4 days. View Amicus Therapeutics' Short Interest. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $103.50 million for the quarter, compared to analysts' expectations of $102.30 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative trailing twelve-month return on equity of 119.46%. Amicus Therapeutics's revenue was up 26.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) earnings per share. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC). What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics updated its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $399.4 million-$399.4 million, compared to the consensus revenue estimate of $396.5 million. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.72%), Vanguard Group Inc. (9.65%), Perceptive Advisors LLC (9.57%), Wellington Management Group LLP (5.14%), Palo Alto Investors LP (3.54%) and Fiera Capital Corp (1.73%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FOLD) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.